Bausch + Lomb is a leading segment focused on eye health, offering a comprehensive portfolio of products for vision care, surgical, and ophthalmic pharmaceuticals. Research and development efforts concentrate on innovative contact lenses, intraocular lenses (IOLs), and treatments for various eye conditions. Technologies include advanced materials science for lens design, surgical instrumentation, and drug delivery systems. This segment addresses a wide range of patient needs, from correcting vision to treating diseases like glaucoma and cataracts, improving patient outcomes and quality of life. Bausch + Lomb holds a strong market position due to its brand recognition, extensive product offerings, and global distribution network. Future opportunities include expanding into emerging markets and developing new therapies for age-related macular degeneration (AMD) and other prevalent eye diseases. Regulatory aspects involve rigorous clinical trials and FDA approvals for new products. Partnerships with ophthalmologists and eye care professionals are crucial for product development and market access.

Salix focuses on gastroenterology, developing and marketing innovative products for the treatment of gastrointestinal disorders. Research and development activities are centered on discovering and developing new therapies for conditions such as irritable bowel syndrome (IBS), ulcerative colitis, and Crohn's disease. Technologies employed include advanced drug formulations, targeted drug delivery systems, and innovative diagnostic tools. The segment aims to improve the lives of patients suffering from chronic gastrointestinal conditions by providing effective and convenient treatment options. Salix has a strong market presence in the United States, driven by its portfolio of branded products and its focus on patient-centric care. Future growth opportunities include expanding the product pipeline with new therapies and expanding into international markets. Regulatory aspects involve obtaining FDA approvals and navigating complex reimbursement landscapes. Partnerships with gastroenterologists and patient advocacy groups are essential for clinical trials and market access.

The International Rx segment encompasses a broad range of pharmaceutical, medical device, and over-the-counter (OTC) products, including Solta products and Bausch + Lomb products, marketed outside of the United States. This segment operates across Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Research and development efforts are focused on adapting existing products for international markets and developing new products tailored to regional needs. Technologies include formulation development, medical device design, and supply chain management. The segment addresses diverse healthcare needs across various therapeutic areas, including eye health, dermatology, and gastroenterology, improving patient access to essential medicines and medical devices. International Rx leverages its global presence and established distribution networks to achieve market penetration. Future opportunities include expanding into emerging markets and introducing new products to address unmet medical needs. Regulatory aspects involve navigating diverse regulatory landscapes and obtaining approvals in multiple countries. Partnerships with local distributors and healthcare providers are crucial for market access and commercial success.

Ortho Dermatologics focuses on the development and commercialization of dermatological products in the United States, as well as Solta medical aesthetic devices internationally. Research and development activities are centered on creating innovative treatments for skin conditions such as acne, psoriasis, and eczema. Technologies include advanced topical formulations, drug delivery systems, and aesthetic device technologies. The segment aims to improve the skin health and quality of life for patients with dermatological conditions. Ortho Dermatologics has a strong market position in the US dermatology market, driven by its portfolio of branded products and its focus on patient-centric care. Future growth opportunities include expanding the product pipeline with new therapies and expanding into international markets. Regulatory aspects involve obtaining FDA approvals and navigating complex reimbursement landscapes. Partnerships with dermatologists and patient advocacy groups are essential for clinical trials and market access.